2012 International Conference on Diabetes and Metabolism (ICDM)

Symposium 11
Genetics in Diabetes

## Genome-wide association study for type 2 diabetes in Japan

Laboratory for Endocrinology and Metabolism
RIKEN Center for Genomic Medicine

Shiro Maeda

Center for Genomic Medicine

遺伝子の違いを知り、ひとりひとりに合った医療を生み出します。

Mean BMI for subjects with age ≥ 15 at 2005

Number of subjects with obesity (BMI ≥ 30): 700,000,000

Number of subjects with overweight (BMI ≥ 25): 2,300,000,000

Percentage of subjects with BMI ≥ 25 in Japanese population
- Age > 20 years -

Men

Women

30.5%

20.8%

15.2%

Ministry of Health, Labour and Welfare, 2009

Diabetes mellitus affects 366,200,000 individuals worldwide at 2011

| 2011年 | 3億6620万人 | ▶ | 2030年 | 5億5180万人 |

欧州
5260万人
▼
6400万人

北米・中南米
3770万人
▼
5120万人

中東・北アフリカ
3280万人
▼
5970万人

南東アジア
7140万人
▼
1億2090万人

西太平洋
1億3190万人
▼
1億8790万人

南・中央アメリカ
2510万人
▼
3990万人

アフリカ
1470万人
▼
2800万人

International Diabetes Federation Diabetes Atlas 3rd Edition（2011）

551,800,000 peoples will be suffered from diabetes at 2030

Medical Cost for diabetes：302,500,000,000US＄

The Present State of Diabetes in Japan

Estimated Number of Diabetes : 10,700,000

Estimated Number of Pre-Diabetes : 14,900,000

One of three in age ≥ 40 might have diabetes

Medical Cost : 1,900,000,000,000 JYE

Discovery of genetic loci for type 2 diabetes

BCL11A
ZBED3
JAZF1   KLF14
CDC123-CAMK1D   TP531NP1
TSPAN8-LGR5   CHCHD9
THADA   KCNQ1
ADAMTS9   CENTD2
NOTCH2   HMGA2
                                      HNF1A
                                      ZFAND6
FTO   PRC1
SLC30A8   DUSP9
HHEX   ADCY5
CDKN2A/B   DGKB/TMEM195
IGF2BP2   GCKR   PROX1
CDKAL1   GCK
TCF2   IRS1
WS1   MTNR1B

2000   2002   2004   2006   2008   2010
PPARG
       KCNJ11
              TCF7L2

Association of polymorphisms in TCF7L2 with type 2 diabetes in a Japanese population
- Type 2 diabetes (T2D) 1,630 vs. Control (CN)1,064 -

| | Risk allele frequencies (%) | | | | P | |
| | Japanese | | European | | Japanese | European |
	T2D	CN	T2D	CN		
DG10S478	3.5	2.3	36	28	0.019	$2 \times 10^{-9}(5 \times 10^{-18})$
rs12255372	3.5	2.2	36	28	0.002	$5 \times 10^{-8}(3 \times 10^{-16})$
rs7903146	5.4	4.2	39	30	0.048	$2 \times 10^{-9}(2 \times 10^{-17})$

(Hayashi T et al. *Diabetologia*, 2007)

Variations in the *HHEX* gene are associated with increased risk of type 2 diabetes in the Japanese population

M. Horikoshi · K. Hara · C. Ito · N. Shojima ·
R. Nagai · K. Ueki · P. Froguel · T. Kadowaki

Many of European GWAS-derived loci are associated with type 2 diabetes also in the Japanese, but the others are not.

Association of *CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8,* and *KCNJ11* With Susceptibility to Type 2 Diabetes in a Japanese Population

Shintaro Omori,[1,2] Yasushi Tanaka,[2] Atsushi Takahashi,[3] Hiroshi Hirose,[4] Atsunori Kashiwagi,[5] Kohei Kaku,[6] Ryuzo Kawamori,[7] Yusuke Nakamura,[8] and Shiro Maeda[1]

Comparison of risk allele frequencies between Japanese and European populations

Gene	Chromosome	SNP	Japanese(%)	European(%)
TCF7L2	10q25.3	rs7903146	4.2	30.0
IGF2BP2	3q27.2	rs4402960	29.3	31.3
CDKN2A/B	9p21	rs10811661	56.1	84.1
HHEX	10q23	rs1111875	28.4	57.7
SLC30A8	8q24.11	rs13266634	60.0	63.4
CDKAL1	6p22.3	rs7756992	47.4	23.2
FTO	16q12.2	rs9939609	19.4	38.5
KCNJ11	11p15.1	rs5219	35.5	46.4
PPARG	3p25	rs1801282	97.3	82.4
JAZF1	7p15	rs864745	78.5	50.1
CDC123-CAMK1D	10p13	rs12779790	14.9	18.3
TSPAN8-LGR5	12q21	rs7961581	21.3	26.9
THADA	2p21	rs7578597	100	90.2
ADAMTS9	3p14	rs4607103	59.9	76.1
NOTCH2	1p13-p11	rs10923931	1.7	10.6

(Hayashi et al. *Diabetologia*, 2007, Omori et al. *Diabetes*, 2008)

Genome-Wide Association Studies in Japan

1. Millennium Genome Project
2. BioBank Japan Project

Two Japanese GWAS identified *KCNQ1* at 11q15 as strong susceptibility locus for type 2 diabetes

Millennium genome project

BioBank Japan project

Association of SNPs in the KCNQ1 with type 2 diabetes across different ethnicities

rs2237897	risk allele freq		OR (95% CI)	P
	T2DM	control		
Japanese(3522:1320)	0.68	0.61	1.41(1.29-1.55)	6.8×10^{-13}
Singaporean(1433:1735)	0.69	0.65	1.22(1.09-1.35)	2.4×10^{-4}
Dane(3891:4888)	0.97	0.96	1.36(1.16-1.60)	1.2×10^{-4}

(Unoki H et al. *Nat Genet*, 2008)

rs2237892	risk allele freq		OR (95% CI)	P
	T2DM	control		
Japanese 1(1414:1421)	0.69	0.60	1.49(1.34-1.66)	1.7×10^{-12}
Japanese 2(1481:1513)	0.66	0.59	1.39(1.25-1.54)	1.6×10^{-9}
Japanese 3(1420:1431)	0.68	0.60	1.41(1.26-1.57)	1.1×10^{-9}
Chinese (1356:1540)	0.72	0.65	1.38(1.24-1.55)	4.2×10^{-9}
Korean (752:628)	0.69	0.61	1.41(1.21-1.65)	1.0×10^{-5}
Swedish(2759:3426)	0.95	0.93	1.29(1.11-1.50)	7.2×10^{-4}

(Yasuda K et al. *Nat Genet*, 2008)

KCNQ1 (KVLQT1)
(pottasium votage-gated channel, KQT-like subfamily, member 1)
11p15.5

(Jespersen T et al. Physiology, 2005)

Role of potassium channels in insulin secretion from pancreatic β cells

# Over expression of *KCNQ1* inhibits glucose-induced insulin secretion in MIN6 cells

(Yamagata K et al. *Biochem Biophys Res Commun*, 2011)

Association of SNPs in the *KCNQ1* with type 2 diabetes across different ethnicities

rs2237897	risk allele freq		OR (95% CI)	*P*
	T2DM	control		
Japanese(3522:1320)	0.68	0.61	1.41(1.29-1.55)	6.8×10^{-13}

194 T2D vs. 1,558 controls for 207,097 SNPs

Dane(3891:4888)	0.97	0.96	1.36(1.16-1.60)	1.2×10^{-4}

(Unoki H et al. *Nat Genet*, 2008)

rs2237892	risk allele freq		OR (95% CI)	*P*
	T2DM	control		
Japanese 1(1414:1421)	0.69	0.60	1.49(1.34-1.66)	1.7×10^{-12}

187 T2D vs. 752 controls for 82,343 SNPs

Ja...				$^{-9}$
Japanese 3(1420:1431)	0.68	0.60	1.41(1.26-1.57)	1.1×10^{-9}
Chinese (1356:1540)	0.72	0.65	1.38(1.24-1.55)	4.2×10^{-9}
Korean (752:628)	0.69	0.61	1.41(1.21-1.65)	1.0×10^{-5}
Swedish(2759:3426)	0.95	0.93	1.29(1.11-1.50)	7.2×10^{-4}

(Yasuda K et al. *Nat Genet*, 2008)

Genome-wide association study in the Japanese

1st stage : 4,878 type 2 diabetes vs. 3,345 controls

4,470 type 2 diabetes vs. 3,071 controls belong to the Hondo cluster
For 459,359SNPs

Result of 1st stage analysis

-log₁₀P ... *KCNQ1*

Top 100SNPs were forwarded to stage 2 analysis

2nd stage : 2,886 type 2 diabetes vs. 3,087 controls

Combined results of 1st and 2nd stage analyses

| SNP	Ch	nearest gene	P *	OR (95 %CI)
rs2237892	11	*KCNQ1*	6.66×10^{-18}	1.25 (1.19 – 1.31)
rs2206734	6	*CDKAL1*	1.86×10^{-13}	1.20 (1.14 – 1.26)
rs2383208	9	*CDKN2B*	1.45×10^{-11}	1.19 (1.13 – 1.24)
rs7901695	10	*TCF7L2*	4.53×10^{-9}	1.41 (1.26 – 1.58)
rs6780569	3	*UBE2E2*	6.76×10^{-9}	1.21 (1.14 – 1.30)
rs1470579	3	*IGF2BP2*	5.20×10^{-8}	1.15 (1.09 – 1.21)
rs7172432	15	*C2CD4A/B*	7.48×10^{-8}	1.14 (1.09 – 1.20)

*Combined P values for 1st and 2nd stage calculated by Mantel-Haenszel test

(Yamauchi et al. *Nat Genet,* 2010)

Stage 3 analysis

3,622 type 2 diabetes vs. 2,356 controls

Replication study in other East Asian populations
or in European populations

East Asian
(Singapore, Hong-Kong, South Korea）
4,184 type 2 diabetes vs. 4,154 controls

European
(France, Denmark）
6,980 type 2 diabetes vs. 8,615 controls

	T2D	Control	P	OR (95% CI)
UBE2E2: rs7612463				
Japanese	0.854	0.832	2.27×10^{-9}	1.19 (1.12 – 1.26)
Other East Asian	0.825	0.811	0.0306	1.09 (1.01 – 1.18)
East Asian	0.846	0.825	9.16×10^{-10}	1.15 (1.10 – 1.21)

SNP	n	p値	OR (95% C))
rs7612463	9580 T2D vs. 53,810 CN	9.8×10^{-4}	1.10 (1.04 – 1.16)
rs1496653	34.840 T2D vs. 114,981 CN	3.6×10^{-9}	1.09 (1.06 – 1.12)

European	0.590	0.566	6.36×10^{-5}	1.10 (1.05 – 1.15)
Total	0.606	0.582	8.78×10^{-14}	1.11 (1.08 – 1.14)

(Yamauchi et al. *Nat Genet,* 2010)

UBE2E2 (ubiquitin-conjugating enzyme E2E2)

- Location: chromosome 3 (3p24.2)

- Expression: ubiquitous, including pancreas, liver, adipose

- Ubiquitin-proteasome system plays a pivotal role in maintaining normal insulin biosynthesis, secretion and signalling especially under conditions that increase ER stress in pancreatic β cells

C2CD4A/B (C2 calcium-dependent domain containing 4A/B)

Alternative symbols: NLF 1/2, FAM148A/B

- Location: chromosome 15 (15q22.2)

- Expression: pancreas, insulin secreting cell lines

- Expressions of C2CD4A/B have been shown to be increased by treatment with pro-inflammatory cytokines

Imputation based GWAS identified a new susceptibility loci for type 2 diabetes at *ANK1* locus ~2,229,890 imputed SNPs~

Association of rs515071 within *ANK1* with type 2 diabetes

population	n	P	OR (95% CI)
Japanese	16,902	1.37×10^{-8}	1.18 (1.12 – 1.25)
Eurpean	22,570	8.54×10^{-4}	1.09 (1.03 – 1.14)

(Imamura M et al. Hum Mol Genet, 2012)

Asian Genetic Epidemiology Network (AGEN)

East Asian T2D GWA meta-analysis

Stage1 : Discovery

✓GWA meta-analysis combining 8 T2D GWA studies
(6,952 cases vs. 11,865 controls)

$P < 5 \times 10^{-4}$

Stage2 : *in silico* replication

✓Validation of 3,756 SNPs selected from Stage1
(295 lead SNPs + their proxy SNPs)
in 3 T2D GWA studies (6,258 cases vs. 5,282 controls)
✓Combined meta-analysis (Stages 1+2)

$P < 10^{-5}$

Stage3 : *de novo* replication

✓Validation of 19 SNPs selected from Stage2
in 5 T2D studies (12,284 cases vs. 13,172 controls)
✓Combined meta-analysis (Stages 1+2+3)

$P < 5 \times 10^{-8}$

Novel T2D SNPs

East Again GWAS meta-analysis identified 8 novel loci for type 2 diabetes

| SNP	chr	Nearest gene(s)	P	P in DIAGRAM*
rs6815464	4	*MAEA*	1.57×10^{-20}	0.00656 (-)
rs7041847	9	*GLIS3*	1.99×10^{-14}	0.0643 (0.00072)
rs6017317	20	*FITM2-R3HDML-HNF4A*	1.12×10^{-11}	0.0147 (-)
rs6467136	7	*GCC1-PAX4*	4.96×10^{-11}	0.489 (0.55)
rs831571	3	*PSMD6*	8.41×10^{-11}	0.445 (0.18)
rs9470794	6	*ZFAND3*	2.06×10^{-10}	0.4 (0.81)
rs3786897	19	*PEPD*	1.30×10^{-8}	0.361 (0.037)
rs1535500	6	*KCNK16*	2.30×10^{-8}	0.921 (-)

* Combined data for stage 1 (DIAGRAMv3) and stage 2 in recent NG paper by Morris AP *et al*. are shown in parenthesis

Discovery of genetic loci for type 2 diabetes

Manhattan plot for the discovery analysis of directly genotyped and imputed SNPs in 5,976 T2D cases and 20,829 controls.

6,209,637 SNPs
(459,359 genotyped＋ 5,750,278 imputed)

Contribution

The Institute of Medical Science, University of Tokyo: Yusuke Nakamura

Department of Medicine, Shiga University of Medical Science: Ryuichi Kikkawa, Atsunori Kashiwagi, Hiroshi Maegawa, Takashi Uzu, Shin-ichi Araki

Department of Metabolic Diseases, Graduate School of Medicine, Tokyo University; Takashi Kadowaki, Toshimasa Yamauchi, Kazuo Hara, Momoko Horikoshi, Hayato Fujita

Department of Medicine, Metabolism and Endocrinology, School of Medicine, Juntendo University; Ryuzo Kawamori, Hirotaka Watada, Akio Kanazawa

Diabetes Center, Tokyo Women's Medical University; Toshihide Hayashi, Nobue Tanaka, Tetsuya Babazono, Yasuhiko Iwamoto, Yasuko Uchigata

Division of Endocrinology and Metabolism, Department of Internal Medicine, Kawasaki Medical School, Kohei Kaku. Yukiko Kanda

Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine; Yasushi Tanaka, Shintaro Omori, Toshihiko Ohsjge, Hisashi Fukuda

Health Center, Keio University; Hiroshi Hirose

National Center for Global Health and Medicine: Masato Kasuga, Kazuki Yasuda

First department of Internal Medicine, Faculty of Medicine, Toyama University: Minoru Iwata, Kazuyuki Tobe

BioBank Japan

Steno Diabetes Center, Denmark: Oluf Pedersen, Torben Hansen

National University of Singapore; Daniel PK Ng

Seoul National University: Kyon Soo Park

Asian Genetic Epidemiology Network